AstraZeneca has reported positive outcomes in the treatment of lung cancer with its drug Tagrisso, leading to a 2.4% increase in its share price. The company also completed a $1.1B acquisition of Icosavax from the University of Washington, and received approval for Tagrisso in another trial, showcasing advancements in its lung cancer portfolio.
'Olive oil drug' shows promise in treating aggressive brain cancer at London hospital https://t.co/szQtpe9Agm
AstraZeneca touts ‘overwhelming’ Tagrisso win among 3 lung cancer portfolio advancements https://t.co/fGeDXZxtzt
AstraZeneca gets new Tagrisso OK as drug succeeds in another trial https://t.co/JejM470tT2 $AZN by @NedPagliarulo
AstraZeneca completes $1.1B acquisition of Univ. of Washington biotech spinout Icosavax https://t.co/SpNujd1ozO
$AZN (+2.4% pre) Astrazeneca share price rises as Tagrisso drug shows ‘highly impactful’ results in lung cancer trial https://t.co/TSDKXVXPCE
AstraZeneca unveils successes in treatment of lung cancer https://t.co/GnvBwA7eNA